1 / 29

IN THE NAME OF GOD Elham Faghihimani endocrinologist

IN THE NAME OF GOD Elham Faghihimani endocrinologist. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metab . October 22, 2013. Diagnosis of PCOS. two of the three following criteria are met : androgen excess,

reba
Télécharger la présentation

IN THE NAME OF GOD Elham Faghihimani endocrinologist

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IN THE NAME OF GOD • ElhamFaghihimani • endocrinologist

  2. Diagnosis and Treatment of Polycystic OvarySyndrome: An Endocrine Society Clinical PracticeGuideline J ClinEndocrinMetab. October 22, 2013

  3. Diagnosis of PCOS • two of the three following criteria are met: • androgen excess, • ovulatorydysfunction, or • polycystic ovaries (PCO)

  4. Androgen status • Clinical hyperandrogenismmay include hirsutism (defined as excessive terminal hair that appears in a male pattern), acne, or androgenic alopecia. • Biochemical hyperandrogenismrefers to an elevated serum androgen level

  5. Menstrual history • Anovulation may manifest as frequent bleeding at intervals 21 d or infrequent bleeding at intervals 35 d. • bleeding may be anovulatorydespite falling at a normal interval (25–35 d).

  6. Ovarian appearance • The PCO morphology has been defined by the presence of 12 or more follicles 2–9 mm in diameter • and/or an increased ovarian volume 10 mL (without a cyst or dominant follicle) in either ovary

  7. CASES • 25yrs, female, irregular mense, hirsutism and normal US of ovaries. • 19yrs, female, amenorrhea for2yrs and polycystic ovaries on US • 40yrs, female, infertile, irregular mense, acne and hirsutim, large ovaries

  8. diagnosis • history • Physical examination • Laberatory tests

  9. Disorders that mimic the clinical features of PCOS are excluded. • thyroid disease, • hyperprolactinemia, • and nonclassic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone [17-OHP])

  10. CAH • Screening may first be carried out by obtaining an 8:00 a.m. serum level of 17-hydroxyprogesterone in an anovulatory patient on any day • A level of less than 2 ng/mL effectively rules out this diagnosis • The diagnosis of nonclassic adrenal hyperplasia can be made if the basal 17-hydroxyprogesterone level is higher than 8 ng/mL. No further testing is required in these cases.

  11. Values between 2 and 8 ng/Ml an ACTH stimulation test should be used to distinguish nonclassic adrenal hyperplasia from PCOS. A rise of the 17(OH)P Level to at least 10 ng/mL 60 minutes after intravenous injection of ACTH has been considered diagnostic of nonclassic adrenal hyperplasia

  12. Depending on presentation • Hypothalamic amenorrhea • Primary ovarian failure • Androgen secreting tumor • Cushing syndrom • acromegaly

  13. MORBIDITY • Infertility • Pregnancy complications • Endometrial cancer • Obesity • Nonalcoholic fatty liver disease (NAFLD) • obstructive sleep apnea (OSA) • Depression • Type 2 diabetes mellitus OGTT( every 3-5 years)

  14. Cardiovascular risk • We recommend that adolescents and women with PCOS be screened for the following cardiovascular disease risk factors • family history of early cardiovascular disease, cigarette smoking, IGT/T2DM, hypertension, dyslipidemia, OSA, and obesity (especially increased abdominal adiposity)

  15. Treatment • Hormonal contraceptives • lifestyle therapy • Metformin ( womenwho have T2DM or IGT who fail lifestyle modification, For women with menstrual irregularity who cannot take or do not tolerate HCs, we suggest metforminas second-line therapy)

  16. Insulin resistance is associated with abnormal responses of the ovarian follicle to FSH, which lead to anovulation and androgen secretion. This results in noncyclic formation of estrogen from androgens in peripheral tissues. Estradiol together with elevated androgen and insulin levels gives rise to abnormal gonadotropin secretion. This creates an anovulatory state favoring continuous formation of LH, steroid precursors, androgen, and estrogen

  17. Hirsutism • Hirsutism is defined as the presence of terminal (coarse) hair in locations at which hair is not commonly found in women • virilization is a more severe form of androgen excess and implies significantly higher rates of testosterone production. Its manifestations include temporal balding, deepening of voice, decreased breast size, increased muscle mass, loss of female body contours, and clitoral enlargement

  18. Ferriman-gallwey score

  19. Laboratory Tests for the Differential Diagnosis of Androgen Excess • Initial Testing • Total testosterone • Prolactin • Thyroid-stimulating hormone

  20. Laboratory TESTS • A testosterone value of three times the upper-normal range (or >2 ng/mL) suggests a neoplasm, particularly if the clinical history supports this diagnosis. Lower serum testosterone levels occasionally may be associated with virilizing ovarian tumors • Transvaginalultrasonography is the most sensitive method for the detection of an ovarian tumor. • If DHEAS levels exceed 8 µg/mL, adrenal imaging by computed tomography (CT) or MRI should be ordered.

  21. Further Testing Based on Clinical presentation • 17-Hydroxyprogesterone (8:00 a.m.)17(OH)P 60 min after intravenous ACTHCortisol (8:00 a.m.) after 1 mg dexamethasone at midnightDHEAS, Testosterone •   Imaging of ovaries (transvaginalultrasonography)  Imaging of adrenals (abdominal ultrasonography, CT, MRI)

  22. TREATMENT • Oral Contraceptives • Oral contraceptives reduce circulating testosterone and androgen precursors by suppression of LH and stimulation of SHBG levels, thereby reducing hirsutism in hyperandrogenic patients

  23. Spironolactone • an aldosterone antagonist structurally related to progestins. • inhibiting steroidogenesis and acting as an androgen antagonist, AND a significant effect in inhibiting 5α-reductase activity • Dose: 50 to 400 mg daily • Not recommended in pregnancy

  24. CyproteroneAcetate • acts as an antiandrogen by competing with DHT and testosterone for binding to the androgen receptor • daily in doses of 50 to 100 mg on days 5 through 15 of the treatment cycle • ethinylestradiol is added, it is usually administered in 50-µg doses on days 5 through 26

  25. Finasteride • inhibits 5α-reductase activity • Dose: 5mg/day • Not recommended in pregnancy

  26. Metformin and Thiazolidinediones • metformin (1500 to 2700 mg/day) for 6 months significantly reduces hirsutism • 30 mg/day of pioglitazone • studies suggested that insulin-sensitizing agents may be used in the treatment of hirsutism, especially for women who do not wish to use other oral agents. • A moderate diet and exercise program should be recommended

  27. Most patients with PCOS and idiopathic hirsutism respond to this strategy within 1 year. Patients should be encouraged to continue treatment for at least 2 years

  28. 25yrs, female, irregular mense, hirsutism and normal US of ovaries. • 19yrs, female, amenorrhea for2yrs and polycystic ovaries on US • 40yrs, female, infertile, irregular mense, acne and hirsutim, large ovaries

  29. THANK YOU FOR YOUR ATTENTION

More Related